Skip to main content
Premium Trial:

Request an Annual Quote

Icoria, in Transition, Posts 21-Percent Slide in Q2 Revenue; Restructuring Ongoing

NEW YORK, Aug. 16 (GenomeWeb News) - Icoria yesterday reported reduced revenues and narrowed losses for the second quarter of 2005.


Revenues declined 21 percent to $5 million from $6.3 million during the year-ago quarter. While healthcare revenues grew 11 percent, to $2.5 million, agriculture revenues declined by 39 percent, to $2.4 million, mainly due to the sale of Icoria's agricultural genomics business to Monsanto earlier this year.


R&D expenses declined to $5.5 million from $6.8 million during the second quarter of last year.


Icoria's net loss fell 16 percent, to $3 million, or $.08 per share, down from $3.6 million, or $.10 per share, for the same period last year.


"The second quarter was a period of transition for Icoria, and our financial results reflect this," said Douglas Morton, Icoria's interim CEO, in a statement. "We are working to restructure our cost base and to minimize our burn rate without impairing the operations and research activities on which Icoria is building its future."


As of June 30, Icoria had $8.7 million in cash, cash equivalents, and short-term investments.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.